LDH

Humana Selected by Louisiana Health Department to Serve Medicaid Beneficiaries

Retrieved on: 
星期一, 二月 14, 2022
General Health, Other Health, Health, Professional Services, Insurance, History, Health, Food, NYSE, Medicare, Patient, Quality of life, CMS, TRICARE, Pharmacy, Solution, Transport, Louisiana Department of Health, ABD, Center, Centers for Medicare & Medicaid Services, TANF, MMC, CHIP, Population, Ageing, Lists of disasters, Â, Baton Rouge, Louisiana, Physician, Prabhu, Medicaid managed care, LDH, Hurricane Ida, Health insurance, Medicine, Pharmaceutical industry, Hospital, Humana, Medicaid, List of people from Louisiana

(NYSE: HUM) has been notified by the Louisiana Department of Health (LDH) that the LDH intends to award a contract to Humana to deliver health care coverage to Medicaid beneficiaries across the state.

Key Points: 
  • (NYSE: HUM) has been notified by the Louisiana Department of Health (LDH) that the LDH intends to award a contract to Humana to deliver health care coverage to Medicaid beneficiaries across the state.
  • It is an honor and privilege to be chosen by The Louisiana Department of Health to serve people across Louisiana.
  • Humana is one of five health plans selected as part of a statewide Medicaid managed care procurement issued last year.
  • Humana Healthy Horizons is a Medicaid Product of Humana Health Plan, Inc.
    Humana Inc. (NYSE: HUM) is committed to helping our millions of medical and specialty members achieve their best health.

NovelMed's Complement Alternative Pathway Specific Anti-Bb Antibody (NM8074) for Rare Diseases Achieves a Major Milestone

Retrieved on: 
星期一, 一月 31, 2022
AP, MAC, IND, Safety, Lists of diseases, Patient, Therapy, Pathology, Food, Infection, Conditional sentence, Hemolysis, BB, LDH, Thrombus, Inflammation, Properdin, CP, Pharmacokinetics, Serum, Disease, Complement component 5, C5a, Alternative-complement-pathway C3/C5 convertase, PNH, Paroxysmal nocturnal hemoglobinuria, C3b, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, C3a, Pharmaceutical industry, Vaccine, C5, C3, Pegcetacoplan, Eculizumab, Ravulizumab

Through its targeted specificity to the complement alternative pathway (AP), NM8074 is expected to improve upon current treatments such as Soliris, Ultomiris, and Empaveli, which are approved for treatment of a limited number of rare diseases.

Key Points: 
  • Through its targeted specificity to the complement alternative pathway (AP), NM8074 is expected to improve upon current treatments such as Soliris, Ultomiris, and Empaveli, which are approved for treatment of a limited number of rare diseases.
  • NM8074 selectively binds to complement alternative pathway specific protein Bb and inhibits the formation of C3a/C3b, C5a/C5b, and MAC, products that mediate inflammation and tissue damage in numerous diseases.
  • NM8074 carries a mechanistic advantage over current platforms because it targets the disease-specific complement alternative pathway (AP) without blocking the classical pathway (CP) required for host defense.
  • NovelMed is a clinical-stage biopharmaceutical company committed to innovating and developing biologics to treat rare diseases caused by the overactivation of the complement alternative pathway.

Apellis and Sobi Report Empaveli™ (pegcetacoplan) Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population

Retrieved on: 
星期一, 十二月 13, 2021
Standard of care, Nasdaq, Paroxysmal nocturnal hemoglobinuria, PNH, Week, APLS, Patient, Disease, GLOBE, ASH, Society, LDH, Pharmaceutical industry

EMPAVELI has the potential to elevate the standard of care for adults with PNH regardless of prior treatment or baseline hemoglobin levels.

Key Points: 
  • EMPAVELI has the potential to elevate the standard of care for adults with PNH regardless of prior treatment or baseline hemoglobin levels.
  • The PRINCE study (NCT04085601) was a randomized, multi-center, open-label, controlled Phase 3 study in 53 treatment-nave adults with paroxysmal nocturnal hemoglobinuria (PNH).
  • The PEGASUS study (NCT03500549) was a multi-center, randomized, head-to-head Phase 3 study in 80 adults with paroxysmal nocturnal hemoglobinuria (PNH).
  • One patient (less than 1% in clinical studies) experienced a serious allergic reaction which resolved after treatment with antihistamines.

Aspaveli®/Empaveli™ (pegcetacoplan) demonstrated sustained normalisation of clinical measures in a broad PNH patient population

Retrieved on: 
星期一, 十二月 13, 2021
Patient, Hemoglobinuria, Society, Disease, Standard of care, PRINCE, Nasdaq, LDH, Swedish Orphan Biovitrum, PNH, ASH, Pharmaceutical industry

STOCKHOLM, Dec. 13, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today new data demonstrating that Aspaveli®/Empaveli™ (pegcetacoplan) provides consistent, sustained normalisation of clinical measures across patients with paroxysmal nocturnal haemoglobinuria (PNH) who are treatment-naïve and patients with baseline haemoglobin levels greater than or equal to 10.0 g/dL. The data were presented at the American Society of Hematology Annual Meeting (ASH) taking place 11 – 14 December 2021. 

Key Points: 
  • The data were presented at the American Society of Hematology Annual Meeting (ASH) taking place 11 14 December 2021.
  • "Pegcetacoplan has the potential to elevate the standard of care for adults with PNH regardless of prior treatment or baseline haemoglobin levels."
  • The PRINCE study (NCT04085601) was a randomised, multi-centre, open-label, controlledphase 3 study in 53 treatment-nave adults with paroxysmal nocturnal haemoglobinuria (PNH).
  • The PEGASUS study (NCT03500549) was a multi-centre, randomised, head-to-headphase 3 study in 80 adults with paroxysmal nocturnal haemoglobinuria (PNH).

Crescent Canna Registers Legal THC Gummies for Adult Use in Louisiana

Retrieved on: 
星期二, 十一月 30, 2021
CEO, Safety, Industry, Cannabis, Total, Louisiana Department of Health, THC, LDH, Research, GLOBE, Friends, Crescent, Cannabinoid, Airline

Crescent Canna is proud to be the first New Orleans-based business to successfully register Delta-8 THC products in Louisiana.

Key Points: 
  • Crescent Canna is proud to be the first New Orleans-based business to successfully register Delta-8 THC products in Louisiana.
  • Crescent Canna's LDH-registered Delta-8 products include 25 mg Delta-8 THC Sour Space Cadets and 30 mg Delta-8 THC Rocket Bites .
  • Delta-8 THC is a naturally occurring cannabinoidwith psychoactive effects that are similar to but milder than those of its more famous cousin, Delta-9 THC.
  • "We are so proud to finally bring hemp-derived THC products to our friends and customers throughout Louisiana," says Crescent Canna Chief Marketing Officer David Reich.

Positive Phase 2b results in 2nd line melanoma

Retrieved on: 
星期五, 十一月 12, 2021
MSD, Ipilimumab, Safety, SITC, Cancer, DCR, Therapy, Durable, Neoplasm, LBA, Antigen presentation, EST, CEO, RNA, Disease, Pembrolizumab, Immunotherapy, Patient, Annual general meeting, GLOBE, LDH, The Society, Highlight, Society for Immunotherapy of Cancer, CT, Melanoma, FDA, Pharmaceutical industry

MADRID, Spain, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Highlight Therapeutics, ("Highlight"), a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, today announced positive preliminary results of a Phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with advanced melanoma whose disease had progressed on first-line anti-PD1-based therapy. BO-112 is a dsRNA agonist targeting anti-PD1 resistance, which has been successfully tested in several previous Phase 1b studies.

Key Points: 
  • BO-112 is a dsRNA agonist targeting anti-PD1 resistance, which has been successfully tested in several previous Phase 1b studies.
  • "These are potentially game-changing results showing that BO-112 can rescue melanoma patients who have failed first-line immune-therapy with anti-PD1," said Dr Carlos Paya, Executive Chairman of Highlight Therapeutics.
  • These initial Phase 2 results show that BO-112 combined with a leading PD1 inhibitor rescue around 65% of anti-PD1 failing patients, making many of them respond to the combined treatment.
  • With a median follow up of three months, there is a clear clinical benefit in patients with confirmed anti-PD1-resistant melanoma, with a 27% ORR and a 65% DCR, superior to 2nd line Standard of Care in stage III/IV melanoma of ~8% (continuing with anti-PD1 Ab) or 13% (second line ipilimumab).

Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society (CTO

Retrieved on: 
星期五, 十一月 12, 2021
Cancer, Therapy, Breast, Poster, Safety, Ottawa Hospital Research Institute, Bristol Myers Squibb, Intensity, Pain, Columbia University Vagelos College of Physicians and Surgeons, STS, Review, Colon, CTOS, Merck Sharp & Dohme Federal Credit Union, NCI, Injection, Cisplatin, Woman, Ontario Institute for Cancer Research, National Cancer Institute, Survival, Patient, Immunosuppression, Diffusion, FDA, Ipilimumab, Sarcoma, Neoplasm, Division, Pembrolizumab, Publication, Fatigue, Hematology, Vinblastine, NCT, LDH, Surgeon, ECOG, Agency, MD, SHAO, Merck, Immune system, Appetite, Cooperative research and development agreement, BMS, Haematoxylin, Eosin, Company, Development, CRADA, Physician, Assistant, Pharmaceutical industry, Vaccine

These results provide further evidence to continue studying this novel therapeutic drug approach."

Key Points: 
  • These results provide further evidence to continue studying this novel therapeutic drug approach."
  • The data presented included results from 19 patients with different metastatic sarcomas treated with INT230-6 either as a monotherapy (n=10), or in combination with a checkpoint inhibitor (n=8) primarily ipilimumab.
  • For sarcoma subjects dosed to >40% of their total tumor burden, approximately 60% of subjects will be alive at 1 year.
  • Intensity Therapeutics, Inc. is a privately held, clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers.

Positive Phase 2b results in 2nd line melanoma

Retrieved on: 
星期五, 十一月 12, 2021
MSD, Ipilimumab, Safety, SITC, Cancer, DCR, Therapy, Durable, Neoplasm, LBA, Antigen presentation, EST, CEO, RNA, Disease, Pembrolizumab, Immunotherapy, Patient, Annual general meeting, GLOBE, LDH, The Society, Highlight, Society for Immunotherapy of Cancer, CT, Melanoma, FDA, Pharmaceutical industry

BO-112 is a dsRNA agonist targeting anti-PD1 resistance, which has been successfully tested in several previous Phase 1b studies.

Key Points: 
  • BO-112 is a dsRNA agonist targeting anti-PD1 resistance, which has been successfully tested in several previous Phase 1b studies.
  • "These are potentially game-changing results showing that BO-112 can rescue melanoma patients who have failed first-line immune-therapy with anti-PD1," said Dr Carlos Paya, Executive Chairman of Highlight Therapeutics.
  • These initial Phase 2 results show that BO-112 combined with a leading PD1 inhibitor rescue around 65% of anti-PD1 failing patients, making many of them respond to the combined treatment.
  • With a median follow up of three months, there is a clear clinical benefit in patients with confirmed anti-PD1-resistant melanoma, with a 27% ORR and a 65% DCR, superior to 2nd line Standard of Care in stage III/IV melanoma of ~8% (continuing with anti-PD1 Ab) or 13% (second line ipilimumab).

Apellis to Present New Data Reinforcing EMPAVELI™ (pegcetacoplan) Efficacy and Safety in Patients with PNH at the 2021 ASH Annual Meeting

Retrieved on: 
星期四, 十一月 4, 2021
Real-World Evidence, Safety, Congress Center, APLS, Paroxysmal nocturnal hemoglobinuria, Quality, 2021 Essex County Council election, Disease, Correlation and dependence, Ravulizumab, Efficacy, Eculizumab, LDH, ASH, PM, PNH, Effect, Standard of care, Quality of life, Nasdaq, PRINCE, Society, GLOBE, PEGASUS, Week, Georgia World Congress Center, Pharmaceutical industry

The new data further support the positive efficacy and safety profile of EMPAVELI, the first and only targeted C3 therapy, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).

Key Points: 
  • The new data further support the positive efficacy and safety profile of EMPAVELI, the first and only targeted C3 therapy, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
  • The PEGASUS study (NCT03500549) is a multi-center, randomized, head-to-head Phase 3 study in 80 adults with paroxysmal nocturnal hemoglobinuria (PNH).
  • The primary objective of this study was to establish the efficacy and safety of EMPAVELI compared to eculizumab.
  • Closely monitor patients for early signs and symptoms of serious infection and evaluate patients immediately if an infection is suspected.

Dicerna Announces Results for PHYOX™4, Single-Dose Study of Nedosiran in Primary Hyperoxaluria Type 3 (PH3)

Retrieved on: 
星期二, 十月 19, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Back pain, Clinical trial, AES, Roche, Caregiver, Gene, PH3, Form 10-K, Metabolism, Risk, United States Census Bureau, Technology, Observation, Novo Nordisk, COVID-19, Chronic kidney disease, Primary hyperoxaluria, Lists of diseases, Patient, U.S. Securities and Exchange Commission, Tissue, Security (finance), Trial of the century, Skin, Liver, Nephrocalcinosis, LDH, NDA, Therapy, Disease, Mutation, Pain, Research, Intellectual property, Medication, RNA interference, FDA, Safety, Health, PH1, Eli Lilly, PH2, Kidney, Neurodegeneration, Heart, AE, Company, Pharmaceutical industry, Primary Hyperoxaluria (PH), Nedosiran, Dicerna Pharmaceuticals, Inc., PRIMARY HYPEROXALURIA (PH), NEDOSIRAN, DICERNA PHARMACEUTICALS, INC.

Nedosiran demonstrated safety and tolerability results in this trial consistent with previously reported studies in the PHYOX clinical development program.

Key Points: 
  • Nedosiran demonstrated safety and tolerability results in this trial consistent with previously reported studies in the PHYOX clinical development program.
  • Dicerna plans to submit an NDA to the FDA for nedosiran for the treatment of PH1 in the fourth quarter of 2021.
  • I would like to extend our sincere thanks to the patients, caregivers, investigators and their staff involved in the PHYOX4 study for their important contributions.
  • Primary hyperoxaluria (PH) is a family of ultra-rare, life-threatening genetic disorders that initially manifest with complications in the kidneys.